At the news
? NEUTRALIMPACT 4/10 S-3 filed Mar 17, 2026 at 16:17 ET
Atara Biotherapeutics has filed an S-3 shelf registration to register 400,000 shares of common stock for resale by HCR Molag Fund, L.P., a selling stockholder. These shares are issuable upon exercise of a warrant granted in connection with an amendment to a purchase agreement that extended the due date of a $9.0 million milestone payment from June 2026 to January 2028. Atara will not receive proceeds from the resale, but may receive $0.04 from the warrant exercise. The offering represents a 4.9% dilution based on current market cap.
- S-3 filing registers 400,000 shares for resale by HCR Molag Fund, L.P.
- Shares are issuable upon exercise of a warrant with $0.0001 exercise price.
- Warrant was issued in connection with extending a $9.0 million milestone payment due date from June 2026 to January 2028.
- Atara will not receive proceeds from the resale of shares by the selling stockholder.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access